Guardant Health Investor Presentation

Strong financial profile Revenues ($000's) Sample Volumes (1) BioPharma Clinical $29,840 2017 Q3 YTD +94% $57,766 2018 Q3 YTD 20,960 17,304 (+33% 27,981 Gross Profit Margin (2) 20,644 24.7% 7,337 3,656 2017 Q3 YTD 2018 Q3 YTD (1) Clinical volume excludes 352 and 1,382 tests in the first nine months of 2018 and 2017, respectively, from a customer that in March 2018 began processing tests in-house (2) Gross profit margin = gross profit / total revenue Gross profit Total revenue - Cost of precision oncology testing - Cost of development services 2017 Q3 YTD +100% 49.3% 2018 Q3 YTD 26 GUARDANT

View entire presentation